Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lecia V Sequist

Showing results (1-10 of 272) with videos related to

Pageof 28
Sort By:
The Oncologist|April 5, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerLecia V Sequist
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancerLecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Protein degradation/chaperone system and histone deacetylase pathwayLecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patientsLecia V Sequist
The Oncologist|March 22, 2015
The anticipated next season of EGFR inhibitorsLecia V Sequist
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
ROS1-targeted therapy in non-small cell lung cancerLecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Update on epidermal growth factor receptor inhibitor development in lung cancerLecia V Sequist, Rafal Dziadziuszko
Cancer Journal (Sudbury, Mass.)|September 22, 2015
Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment OptionsZofia Piotrowska, Lecia V Sequist
JAMA Oncology|May 20, 2016
Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A ReviewZofia Piotrowska, Lecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 21, 2017
Tackling the Next Generation of Resistance in EGFR-Mutant Lung CancerZofia Piotrowska, Lecia V Sequist
Pageof 28

Showing results (1-10 of 272) with videos related to

Sort By:
Pageof 28
The Oncologist|April 5, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerLecia V Sequist
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancerLecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Protein degradation/chaperone system and histone deacetylase pathwayLecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patientsLecia V Sequist
The Oncologist|March 22, 2015
The anticipated next season of EGFR inhibitorsLecia V Sequist
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
ROS1-targeted therapy in non-small cell lung cancerLecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Update on epidermal growth factor receptor inhibitor development in lung cancerLecia V Sequist, Rafal Dziadziuszko
Cancer Journal (Sudbury, Mass.)|September 22, 2015
Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment OptionsZofia Piotrowska, Lecia V Sequist
JAMA Oncology|May 20, 2016
Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A ReviewZofia Piotrowska, Lecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 21, 2017
Tackling the Next Generation of Resistance in EGFR-Mutant Lung CancerZofia Piotrowska, Lecia V Sequist
Pageof 28